The EMPEROR-Preserved trial demonstrated that the sodium-glucose cotransporter 2 inhibitor empagliflozin reduced the combined endpoint of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), irrespective of diabetic status. Despite the high potential to change clinical practice, the strict trial selection criteria might reduce external validity of these findings. In this analysis on a contemporary real-world population, we showed that almost two-thirds of HFpEF patients would be candidates for initiation of empagliflozin according to EMPEROR-Preserved criteria. Applying only the trial criteria most likely influencing treatment decisions in clinical practice, the proportion of HFpEF patients potentially eligible to empagliflozin rose to 85%. The demonstrated broad eligibility to empagliflozin in this real-world analysis might predict an extensive use of gliflozins in HFpEF population, with a consequent consistent improvement in cardiovascular outcomes of eligible patients.

What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin

Monzo, Luca
Primo
;
2022

Abstract

The EMPEROR-Preserved trial demonstrated that the sodium-glucose cotransporter 2 inhibitor empagliflozin reduced the combined endpoint of cardiovascular death or heart failure hospitalization in patients with heart failure with preserved ejection fraction (HFpEF), irrespective of diabetic status. Despite the high potential to change clinical practice, the strict trial selection criteria might reduce external validity of these findings. In this analysis on a contemporary real-world population, we showed that almost two-thirds of HFpEF patients would be candidates for initiation of empagliflozin according to EMPEROR-Preserved criteria. Applying only the trial criteria most likely influencing treatment decisions in clinical practice, the proportion of HFpEF patients potentially eligible to empagliflozin rose to 85%. The demonstrated broad eligibility to empagliflozin in this real-world analysis might predict an extensive use of gliflozins in HFpEF population, with a consequent consistent improvement in cardiovascular outcomes of eligible patients.
File allegati a questo prodotto
File Dimensione Formato  
Monzo_What_2022.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 578.76 kB
Formato Adobe PDF
578.76 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1651559
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact